NO890989L - ISOCYANOMETHYL COMPOUND AND PROCEDURE FOR THE PREPARATION OF AN OXADIAZOLIMIDAZOBENZODIAZEPINE DERIVATIVE. - Google Patents
ISOCYANOMETHYL COMPOUND AND PROCEDURE FOR THE PREPARATION OF AN OXADIAZOLIMIDAZOBENZODIAZEPINE DERIVATIVE.Info
- Publication number
- NO890989L NO890989L NO890989A NO890989A NO890989L NO 890989 L NO890989 L NO 890989L NO 890989 A NO890989 A NO 890989A NO 890989 A NO890989 A NO 890989A NO 890989 L NO890989 L NO 890989L
- Authority
- NO
- Norway
- Prior art keywords
- compound
- isocyanomethyl
- alkyl
- oxadiazole
- mmol
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 14
- -1 ISOCYANOMETHYL COMPOUND Chemical class 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 title claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 29
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 230000007306 turnover Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 102000004300 GABA-A Receptors Human genes 0.000 description 5
- 108090000839 GABA-A Receptors Proteins 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229960002200 flunitrazepam Drugs 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- KLNFAMGHSZQYHR-UHFFFAOYSA-N imidazo[4,5-i][1,2]benzodiazepine Chemical class C1=CC=NN=C2C3=NC=NC3=CC=C21 KLNFAMGHSZQYHR-UHFFFAOYSA-N 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- BMCZADOABZFKMG-UHFFFAOYSA-N 3-ethyl-5-(isocyanomethyl)-1,2,4-oxadiazole Chemical compound CCC1=NOC(C[N+]#[C-])=N1 BMCZADOABZFKMG-UHFFFAOYSA-N 0.000 description 2
- BGHGVAKKIBOJGS-UHFFFAOYSA-N 5-cyclopropyl-3-(isocyanomethyl)-1,2,4-oxadiazole Chemical compound [C-]#[N+]CC1=NOC(C2CC2)=N1 BGHGVAKKIBOJGS-UHFFFAOYSA-N 0.000 description 2
- YDQHQLYSPHGVPM-UHFFFAOYSA-N 5-ethyl-3-(isocyanomethyl)-1,2,4-oxadiazole Chemical compound CCC1=NC(C[N+]#[C-])=NO1 YDQHQLYSPHGVPM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 238000009739 binding Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- HULPLKDCCLPDEX-UHFFFAOYSA-N n-[(3-cyclopropyl-1,2,4-oxadiazol-5-yl)methyl]formamide Chemical compound O1C(CNC=O)=NC(C2CC2)=N1 HULPLKDCCLPDEX-UHFFFAOYSA-N 0.000 description 2
- OYPIXUZKTODLAC-UHFFFAOYSA-N n-[(5-cyclopropyl-1,2,4-oxadiazol-3-yl)methyl]formamide Chemical compound O=CNCC1=NOC(C2CC2)=N1 OYPIXUZKTODLAC-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 2
- 210000004129 prosencephalon Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000003345 scintillation counting Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZVAPWJGRRUHKGP-UHFFFAOYSA-N 1h-1,5-benzodiazepine Chemical class N1C=CC=NC2=CC=CC=C12 ZVAPWJGRRUHKGP-UHFFFAOYSA-N 0.000 description 1
- DCWGHEUBIALONA-UHFFFAOYSA-N 3-(3-ethyl-1,2,4-oxadiazol-5-yl)-5,7-dimethyl-4h-imidazo[1,5-a][1,4]benzodiazepin-6-one Chemical compound CCC1=NOC(C2=C3N(C4=CC=CC(C)=C4C(=O)N(C)C3)C=N2)=N1 DCWGHEUBIALONA-UHFFFAOYSA-N 0.000 description 1
- OOHTWJGRUZYQST-UHFFFAOYSA-N 3-(isocyanomethyl)-5-(methoxymethyl)-1,2,4-oxadiazole Chemical compound COCC1=NC(C[N+]#[C-])=NO1 OOHTWJGRUZYQST-UHFFFAOYSA-N 0.000 description 1
- UNCHAYRENXIZBL-UHFFFAOYSA-N 3-(isocyanomethyl)-5-methyl-1,2,4-oxadiazole Chemical compound CC1=NC(C[N+]#[C-])=NO1 UNCHAYRENXIZBL-UHFFFAOYSA-N 0.000 description 1
- KFVVSDPKGPUSEL-UHFFFAOYSA-N 3-cyclopropyl-5-(isocyanomethyl)-1,2,4-oxadiazole Chemical compound O1C(C[N+]#[C-])=NC(C2CC2)=N1 KFVVSDPKGPUSEL-UHFFFAOYSA-N 0.000 description 1
- VYJBPROLJIGKEL-UHFFFAOYSA-N 4,6-dimethyl-1,3-dihydro-1,4-benzodiazepine-2,5-dione Chemical compound O=C1N(C)CC(=O)NC2=CC=CC(C)=C21 VYJBPROLJIGKEL-UHFFFAOYSA-N 0.000 description 1
- OUVUFAZUKYKNCJ-UHFFFAOYSA-N 4-imidazo[4,5-i][1,2]benzodiazepin-3-yloxadiazole Chemical class N=1N=C2C3=NC=NC3=CC=C2C=CC=1C1=CON=N1 OUVUFAZUKYKNCJ-UHFFFAOYSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- LGTLXDJOAJDFLR-UHFFFAOYSA-N diethyl chlorophosphate Chemical compound CCOP(Cl)(=O)OCC LGTLXDJOAJDFLR-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- GMBCCEOJUWMBPF-UHFFFAOYSA-N ethyl 2-formamidoacetate Chemical compound CCOC(=O)CNC=O GMBCCEOJUWMBPF-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- OMCUPXRCMTUDHI-UHFFFAOYSA-N n'-hydroxycyclopropanecarboximidamide Chemical compound ON=C(N)C1CC1 OMCUPXRCMTUDHI-UHFFFAOYSA-N 0.000 description 1
- VVWSIHMDVHQTNC-UHFFFAOYSA-N n-[(3-ethyl-1,2,4-oxadiazol-5-yl)methyl]formamide Chemical compound CCC1=NOC(CNC=O)=N1 VVWSIHMDVHQTNC-UHFFFAOYSA-N 0.000 description 1
- RVHCGNUSTHNQRK-UHFFFAOYSA-N n-[(5-ethyl-1,2,4-oxadiazol-3-yl)methyl]formamide Chemical compound CCC1=NC(CNC=O)=NO1 RVHCGNUSTHNQRK-UHFFFAOYSA-N 0.000 description 1
- UGNUTYFQHHSKSG-UHFFFAOYSA-N n-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]formamide Chemical compound CC1=NC(CNC=O)=NO1 UGNUTYFQHHSKSG-UHFFFAOYSA-N 0.000 description 1
- OTGLNRCZPSDGDN-UHFFFAOYSA-N n-[2-[5-(methoxymethyl)-1,2,4-oxadiazol-3-yl]ethyl]formamide Chemical compound COCC1=NC(CCNC=O)=NO1 OTGLNRCZPSDGDN-UHFFFAOYSA-N 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 230000001777 nootropic effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Description
Foreliggende oppfinnelse vedrører en hittil ukjent isocyanometylforbindelse og en fremgangsmåte for anvendelse av denne forbindelsen til fremstilling av et oksadiazolimidazo-benzodiazepinderivat. Dette derivatet er anvendelig i psykofarmasøytiske preparater så som krampehemmende midler, angsthemmende midler, hypnotiske midler og nootropiske midler. The present invention relates to a previously unknown isocyanomethyl compound and a method for using this compound to produce an oxadiazolimidazo-benzodiazepine derivative. This derivative is applicable in psychopharmaceutical preparations such as anticonvulsants, anxiolytics, hypnotics and nootropics.
Det nevnte oksadiazolylimidazobenzodiazepinderivatet har den generelle formelen I: hvor R 3 har formelen Said oxadiazolylimidazobenzodiazepine derivative has the general formula I: where R 3 has the formula
hvor R" betyr C^_^-alkyl eller C3_^,-cykloalkyl, og R"' betyr C^_^-alkyl eller C^^-cykloalkyl; R<4>og R<5>betyr sammen en 2-6 leddet alkylenkjede og RA betyr C^_^,-alkyl. where R" means C^_^-alkyl or C3_^,-cycloalkyl, and R"' means C^_^-alkyl or C^^-cycloalkyl; R<4> and R<5> together mean a 2-6 membered alkylene chain and RA means C^_^,-alkyl.
Europeisk patentsøknad nr. 109.921 beskriver forskjellige oksadlazolylderivater av imidazobenzodiazepiner som er i stand til å fortrenge flunitrazepam fra benzodiazepinreceptorer. European Patent Application No. 109,921 describes various oxadlazolyl derivatives of imidazobenzodiazepines capable of displacing flunitrazepam from benzodiazepine receptors.
Europeisk patentsøknad nr. 150.040 beskriver også oksadlazolylderivater av imidazobenzodiazepiner. Selv om denne patentsøknadens generiske krav innbefatter forbindelser med generell formel II hvor r<3>,R4, r5 og RA har de ovenfor angitte betydninger, inneholder europeisk patentsøknad nr. 150.040 ingen spesifikk omtale av forbindelser hvor RA betyr alkoksy eller lavere a<1>kyl. European Patent Application No. 150,040 also describes oxadlazolyl derivatives of imidazobenzodiazepines. Although the generic claims of this patent application include compounds of general formula II in which r<3>, R4, r5 and RA have the above meanings, European Patent Application No. 150,040 contains no specific mention of compounds in which RA means alkoxy or lower a<1> chill.
Det har vist seg at de hittil ukjente forbindelsene fremstilt ved fremgangsmåten ifølge oppfinnelsen har forbedrede farmasøytiske egenskaper sammenlignet med kjente, beslektede forbindelser. It has been shown that the hitherto unknown compounds produced by the method according to the invention have improved pharmaceutical properties compared to known, related compounds.
Det er velkjent (Squires, R.F.og Bræstrup, C, Nature (London) 266, (1977) 734) at spesifikke posisjoner i sentralnervesystemet utviser en høy spesifikk aktivitet for binding av 1,4- og 1,5-benzodiazepiner. Disse posisjonene kalles benzodiazepinreceptorer. It is well known (Squires, R.F. and Bræstrup, C, Nature (London) 266, (1977) 734) that specific positions in the central nervous system exhibit a high specific activity for binding 1,4- and 1,5-benzodiazepines. These positions are called benzodiazepine receptors.
Den farmasøytiske virkningen av slike forbindelser kan illustreres ved å bestemme deres evne til å fortrenge radioaktivt merket flunitrazepam og imidazobenzodiazepiner<3>H-R0 15-1788 fra slike benzodiazepinreceptorer. The pharmaceutical action of such compounds can be illustrated by determining their ability to displace radiolabeled flunitrazepam and imidazobenzodiazepines<3>H-R0 15-1788 from such benzodiazepine receptors.
Fortrengningsaktiviteten for forbindelsene er fastslått ved å bestemme IC5Qog ED50verdiene. IC50verdien representerer den kontraksjonen (nM, 30'C), som forårsaker en fortrengning av 50% av den spesifikk bindingen av<3>H-RP 15-1788 fra benzodiazepinreceptorer i prøver som omfatter en samlet mengde på 1 ml. The displacement activity of the compounds is determined by determining the IC 50 and ED 50 values. The IC50 value represents the contraction (nM, 30'C) which causes a displacement of 50% of the specific binding of <3>H-RP 15-1788 from benzodiazepine receptors in samples comprising a total amount of 1 ml.
Fortrengningsforsøket foretas på følgende måte:The displacement test is carried out in the following way:
750 pl rottehjerne cortikalmembranhomogenat inkuberes med 100 pl av 5 nM<3>H-R0 15-1788 i vann ved 30° C. 100 pl av en oppløsning av forsøksforbindelsen og 50 pl Krebs buffer tilsettes. Etter inkubering stoppes bindingsreaksjonen ved filtrering gjennom "Whatman GF/B" glassfiberfiltre etterfulgt av 2 x 5 ml vask med iskald buffer, og radioaktiviteten måles ved scintillasjonstelling. IC5Qbestemmes på basis av minst 4 konsentrasjoner av forsøksforbindelsen og ved "log/probit" analyse av resultatene. 750 µl of rat brain cortical membrane homogenate is incubated with 100 µl of 5 nM<3>H-R0 15-1788 in water at 30° C. 100 µl of a solution of the test compound and 50 µl of Krebs buffer are added. After incubation, the binding reaction is stopped by filtration through "Whatman GF/B" glass fiber filters followed by a 2 x 5 ml wash with ice-cold buffer, and the radioactivity is measured by scintillation counting. IC5Q is determined on the basis of at least 4 concentrations of the test compound and by "log/probit" analysis of the results.
ED5Q-verdien representerer den dose (mg/kg) av en forsøksfor-bindelse, hvormed den spesifikke bindingen av flunitrazepam til benzodiazepinreceptorer i en levende hjerne reduseres til 50$ av kontrollverdien. The ED5Q value represents the dose (mg/kg) of a test compound at which the specific binding of flunitrazepam to benzodiazepine receptors in a living brain is reduced to 50% of the control value.
Et slikt in vivo forsøk utføres på følgende måte:Such an in vivo experiment is carried out in the following way:
Grupper av mus injiseres med forsøksforbindelsen i forskjellige doser og vanligvis subkutant. 15 minutter senere gis<3>H-flunitrazepam intravenøst til musene og etter ytterligere 20 minutter avlives musene, deres forhjernemembraner fjernes, og radioaktiviteten i disse forhjernemembranene måles ved scintillasjonstelling. EDsg-verdien bestemmes fra dose-responskurver. Groups of mice are injected with the test compound in different doses and usually subcutaneously. 15 minutes later<3>H-flunitrazepam is given intravenously to the mice and after another 20 minutes the mice are euthanized, their forebrain membranes are removed, and the radioactivity in these forebrain membranes is measured by scintillation counting. The EDsg value is determined from dose-response curves.
Fremgangsmåten ifølge oppfinnelsen er kjennetegnet ved at en forbindelse med den generelle formel hvor R<4>, R*5 og R^ har de ovenfor angitte betydninger og Y betyr en avspaltbar gruppe, omsettes med en forbindelse av formelen The method according to the invention is characterized by the fact that a compound of the general formula where R<4>, R*5 and R^ have the meanings indicated above and Y means a leaving group, is reacted with a compound of the formula
hvor R<3>har den ovenfor angitte betydningen. where R<3> has the meaning given above.
Resultatene som oppnås ved å underkaste noen forbindelser fremstilt ved fremgangsmåten ifølge oppfinnelsen forsøk for bestemmelse av IC50- og ED5Q-verdier, vil fremgå av den etterfølgende tabell 1. Utgangsmaterialene for anvendelse ved fremgangsmåten Ifølge oppfinnelsen kan fremstilles fra kommersielt tilgjengelige benzenderivater ved anvendelse av fremgangsmåten beskrevet i de europeiske patentsøknadene nr. 109.921 og 27.214 og Synthesis, bind 10, s. 681-2. The results obtained by subjecting some compounds produced by the method according to the invention to tests for the determination of IC50 and ED5Q values will appear in the following table 1. The starting materials for use in the method according to the invention can be prepared from commercially available benzene derivatives using the method described in European Patent Applications Nos. 109,921 and 27,214 and Synthesis, Volume 10, pp. 681-2.
Forbindelsene fremstilt ved fremgangsmåten ifølge oppfinnelsen kan anvendes til formulering av farmasøytiske preparater, f.eks. oral og parenteral administrering til pattedyr, innbefattende mennesker, i overensstemmelse med vanlige galeniske farmasøytiske fremgangsmåter. The compounds produced by the method according to the invention can be used for the formulation of pharmaceutical preparations, e.g. oral and parenteral administration to mammals, including humans, in accordance with standard galenic pharmaceutical procedures.
Vanlige tilsetningsstoffer er slike farmasøytisk akseptable organiske eller uorganiske baererstof f er som er egnede for parenteral eller enteral administrering, og som ikke på skadelig måte reagerer med de aktive forbindelsene. Common additives are such pharmaceutically acceptable organic or inorganic carriers which are suitable for parenteral or enteral administration and which do not react in a deleterious manner with the active compounds.
Eksempler på slike bærere er vann, saltoppløsninger, alkoholer, polyetylenglykoler, polyhydroksy-etoksylert ricinusolje, gelatin, laktose, amylose, magnesiumstearat, tåkum, kiselsyre, fettsyremonoglycerider og fettsyrediglyce-rider, pentaerytritolfettsyreestere, hydroksymetylcellulose og polyvinylpyrrolidon. Examples of such carriers are water, saline solutions, alcohols, polyethylene glycols, polyhydroxy-ethoxylated castor oil, gelatin, lactose, amylose, magnesium stearate, foam, silicic acid, fatty acid monoglycerides and fatty acid diglycerides, pentaerythritol fatty acid esters, hydroxymethylcellulose and polyvinylpyrrolidone.
De farmasøytiske preparatene kan steriliseres og, om ønsket, blandes med slike hjelpemidler som f.eks. smøremidler, konserveringsmidler, stabilisatorer, fuktemidler, emul-geringsmidler, salter til påvirkning av osmotisk trykk, buffere og/eller fargestoffer og lignende, som ikke på skadelig måte reagerer med de aktive forbindelsene. The pharmaceutical preparations can be sterilized and, if desired, mixed with such aids as e.g. lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers and/or dyes and the like, which do not react in a harmful way with the active compounds.
For parenteral anvendelse er injiserbare oppløsninger eller suspensjoner spesielt egnede, og fortrinnsvis vandige oppløsninger med den aktive forbindelsen oppløst i poly-hydroksylert ricinusolje. For parenteral use, injectable solutions or suspensions are particularly suitable, and preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
Ampuller er hensiktsmessige enhetsdoser.Ampoules are appropriate unit doses.
For oral anvendelse er tabletter, drageer eller kapsler, som inneholder talkum og/eller en karbohydratbærer eller bindemiddel eller lignende, spesielt egnede, idet bæreren fortrinnsvis er laktose og/eller maisstivelse og/eller potetstivelse. En sirup, eleksir eller lignende kan anvendes, hvori det kan benyttes en søtet bærer. For oral use, tablets, dragees or capsules containing talc and/or a carbohydrate carrier or binder or the like are particularly suitable, the carrier preferably being lactose and/or corn starch and/or potato starch. A syrup, elixir or the like can be used, in which a sweetened carrier can be used.
Generelt anvendes forbindelsene i enhetsdoseformer, idet enhetsdosen omfatter 0,05-100 mg i en farmasøytisk akseptabel bærer. In general, the compounds are used in unit dose forms, the unit dose comprising 0.05-100 mg in a pharmaceutically acceptable carrier.
Dosen av forbindelsene fremstilt ved fremgangsmåten Ifølge oppfinnelsen er 0,1-300 mg/dag, fortrinnsvis 1-30 mg/dag, når de administreres til pasienter, f.eks. mennesker, som legemiddel. The dose of the compounds produced by the method according to the invention is 0.1-300 mg/day, preferably 1-30 mg/day, when administered to patients, e.g. people, as medicine.
En typisk tablett, som kan fremstilles ved konvensjonelle A typical tablet, which can be produced by conventional
tabletteringsteknikker, inneholder:tableting techniques, includes:
Oppfinnelsen skal i det følgende beskrives nærmere under henvisning til følgende eksempel: In the following, the invention will be described in more detail with reference to the following example:
EksempelExample
A. 3-cyklopropyl-5-isocyanometyl-l,2,4-oksazidazolA. 3-Cyclopropyl-5-isocyanomethyl-1,2,4-oxazidazole
a. 3-cyklopropyl-5-formylaminometyl-l,2,4-oksadiazola. 3-cyclopropyl-5-formylaminomethyl-1,2,4-oxadiazole
En oppløsning av etylformylaminometylkarboksylat (150 mmol) og cyklopropylkarboksamidoksim (100 mmol) i 10056 EtOH (100 ml) tilsettes Na (200 mg) og en knust molekylsikt (4A) (10 g). Den derved oppnådde blandingen omrøres og oppvarmes til tilbakeløp i 8 timer. Blandingen avkjøles til romtemperatur, filtreres gjennom filter og filtratet Inndampes i vakuum. Den oljeaktige inndampingsresten oppdeles i CHCI3fase, som tørkes med Na2S04og inndampes. To a solution of ethylformylaminomethylcarboxylate (150 mmol) and cyclopropylcarboxamidoxime (100 mmol) in 10056 EtOH (100 mL) is added Na (200 mg) and a crushed molecular sieve (4A) (10 g). The resulting mixture is stirred and heated to reflux for 8 hours. The mixture is cooled to room temperature, filtered through a filter and the filtrate evaporated in vacuo. The oily evaporation residue is divided into the CHCl3 phase, which is dried with Na2SO4 and evaporated.
b. 3-cyklopropyl-5-isocyanometyl-l,2,4-oksadiazolb. 3-cyclopropyl-5-isocyanomethyl-1,2,4-oxadiazole
En omrørt blanding av 3-cyklopropyl-5-formylamlnometyl-l,2,4-oksadiazol (60 mmol) og trietylamin (176 mmol) i CH2C12(100 ml) tilsettes dråpvis POCI3(60 mmol) ved 0°C. Blandingen får deretter stå i 30 minutter med omrøring ved 0°C, hvoretter det tilsettes en oppløsning av NaC03(60 mmol) I HgO (50 ml). Blandingen oppvarmes til romtemperatur, hvoretter den organiske fasen fraskilles, tørkes og inndampes i vakuum. Inndampingsresten behandles med eter, dekanteres, og oppløsningen inndampes for dannelse av den ovenfor nevnte forbindelsen i form av en olje. To a stirred mixture of 3-cyclopropyl-5-formylaminomethyl-1,2,4-oxadiazole (60 mmol) and triethylamine (176 mmol) in CH 2 Cl 2 (100 ml) is added dropwise POCl 3 (60 mmol) at 0°C. The mixture is then allowed to stand for 30 minutes with stirring at 0°C, after which a solution of NaCO 3 (60 mmol) in HgO (50 ml) is added. The mixture is heated to room temperature, after which the organic phase is separated, dried and evaporated in a vacuum. The evaporation residue is treated with ether, decanted, and the solution is evaporated to form the above-mentioned compound in the form of an oil.
Oljen benyttes uten ytterligere rensing.The oil is used without further purification.
IR: cm-<1>: 2160. IR: cm-<1>: 2160.
3-etyl-5-isocyanometyl-l,2,4-oksadiazol fremstilles fra 3-etyl-5-formylaminometyl-l,2,4-oksadiazol på lignende måte. IR: cm-<1>: 2170. 3-Ethyl-5-isocyanomethyl-1,2,4-oxadiazole is prepared from 3-ethyl-5-formylaminomethyl-1,2,4-oxadiazole in a similar manner. IR: cm-<1>: 2170.
B. 5-cyklopropyl-3-isocyanometyl-l,2,4-oksadiazolB. 5-cyclopropyl-3-isocyanomethyl-1,2,4-oxadiazole
a. Formylaminometyl-karboksamidoksima. Formylaminomethyl-carboxamidoxime
0,55 mol nyutskilt hydroksylamin oppløst i 370 ml metanol tilsettes til 53,6 g (0,638 mol) N-formylaminoacetonitril. Et isbad benyttes for å holde temperaturen under 20°C under tilsetningen. Oppløsningen får stå over natten ved romtemperatur, hvoretter den inndampes for dannelse av den ovenfor nevnte forbindelsen i form av bleke krystaller. 0.55 mol of newly separated hydroxylamine dissolved in 370 ml of methanol is added to 53.6 g (0.638 mol) of N-formylaminoacetonitrile. An ice bath is used to keep the temperature below 20°C during the addition. The solution is allowed to stand overnight at room temperature, after which it is evaporated to form the above-mentioned compound in the form of pale crystals.
Dekomponering: 104-110°C.Decomposition: 104-110°C.
b. 3-formylaminometyl-5-etyl-l,2,4-oksadiazolb. 3-Formylaminomethyl-5-ethyl-1,2,4-oxadiazole
En blanding av 70 ml etylpropionat, 20 g formylaminometyl-karboksamidoksim, 1 g natrium og 30 g av en knust molekylar-sikt (4Å) oppvarmes til tilbakeløp I 300 ml absolutt EtOH i 5 timer. Reaksjonsblandingen filtreres og filtratet inndampes. Den oljeaktige inndampingsresten oppslemmes i 300 ml CHCI3, filtreres, og filtratet inndampes for dannelse av ovennevnte forbindelse i form av en olje. A mixture of 70 ml of ethyl propionate, 20 g of formylaminomethylcarboxamidoxime, 1 g of sodium and 30 g of a crushed molecular sieve (4Å) is heated to reflux in 300 ml of absolute EtOH for 5 hours. The reaction mixture is filtered and the filtrate is evaporated. The oily evaporation residue is slurried in 300 ml of CHCl3, filtered, and the filtrate is evaporated to form the above compound in the form of an oil.
HNMR (60 MHz, CDCI3) S (ppm): 1,4 (3H, t, J=8 Hz), 2,9 (2H, q,J = Hz), 4,55 (2H,s), 7,8 (1H), bred-NH), 8,25 (lH,s). HNMR (60 MHz, CDCl3) S (ppm): 1.4 (3H, t, J=8 Hz), 2.9 (2H, q,J = Hz), 4.55 (2H,s), 7, 8 (1H), broad-NH), 8.25 (1H,s).
På lignende måte syntetiseres følgende forbindelser ut fra passende etylestere: In a similar manner, the following compounds are synthesized from the appropriate ethyl esters:
3-formylaminometyl-5-cyklopropyl-l,2,4-oksadiazol.3-Formylaminomethyl-5-cyclopropyl-1,2,4-oxadiazole.
H-NMR (60 MHz, CDCI3) S (ppm): 1,2 (4H,m) 2,8 (lH,m), 4,5 (2H,d,J=6Hz), 7,8 (1H, bred-NH), 8,2 (1H, s). 3-formylaminometyl-5-metyl-l,2,4-oksadiazol. H-NMR (60 MHz, CDCl3) S (ppm): 1.2 (4H,m) 2.8 (1H,m), 4.5 (2H,d,J=6Hz), 7.8 (1H, broad-NH), 8.2 (1H, s). 3-Formylaminomethyl-5-methyl-1,2,4-oxadiazole.
H-NMR (60 MHz, CDCI3) S (ppm_ 2,6 (3H, s), 4,6 (2H, d, J=3 Hz), 7,4 (1H, bred NH), 8,25 (1H, s). H-NMR (60 MHz, CDCl3) S (ppm_ 2.6 (3H, s), 4.6 (2H, d, J=3 Hz), 7.4 (1H, broad NH), 8.25 (1H , pp).
3-formylaminoetyl-5-metoksymetyl-l,2,4-oksadiazol.3-Formylaminoethyl-5-methoxymethyl-1,2,4-oxadiazole.
H-NMR (60 MHz, CDCI3) S (ppm): 3,5 (3H, s), 4,7 (4H, s+d, J=6 Hz), 7,8 (1H, bred-NH), 8,25 (1H, s). H-NMR (60 MHz, CDCl3) S (ppm): 3.5 (3H, s), 4.7 (4H, s+d, J=6 Hz), 7.8 (1H, broad-NH), 8.25 (1H, p).
c. 5-cyklopropyl-3-isocyanometyl-l,2,4-oksadiazolc. 5-cyclopropyl-3-isocyanomethyl-1,2,4-oxadiazole
En omrørt oppløsning av 5-cyklopropyl-3-formylaminometyl-1,2,4-oksadiazol (60 mmol) og trietylamin (176 mmol) i CHgClg (100 ml) tilsettes dråpvis til P0C13(60 mmol) ved 0°C. Blandingen får stå i 30 minutter med omrøring ved 0°C, hvoretter det tilsettes en oppløsning av NagCC^(60 mmol) i HgO (50 ml). Blandingen oppvarmes til romtemperatur, hvoretter den organiske fasen fraskilles, tørkes og inndampes i vakuum. Inndampingsresten behandles med eter, dekanteres og oppløsningen inndampes for dannelse av ovennevnte forbindelse i form av en olje. A stirred solution of 5-cyclopropyl-3-formylaminomethyl-1,2,4-oxadiazole (60 mmol) and triethylamine (176 mmol) in CHgCl 2 (100 mL) is added dropwise to POCl 3 (60 mmol) at 0°C. The mixture is allowed to stand for 30 minutes with stirring at 0°C, after which a solution of NagCC^ (60 mmol) in HgO (50 ml) is added. The mixture is heated to room temperature, after which the organic phase is separated, dried and evaporated in a vacuum. The evaporation residue is treated with ether, decanted and the solution is evaporated to form the above compound in the form of an oil.
Oljen benyttes uten ytterligere rensing.The oil is used without further purification.
IR: cm-<1>: 2160. IR: cm-<1>: 2160.
5-etyl-3-isocyanometyl-l,2,4-oksadiazol, 5-metyl-3-isocyano-metyl-1,2,4-oksadiazol og 5-metoksymetyl-3-isocyanometyl-1,2,4-oksadiazol fremstilles på lignende måte. Alle forbindelsene er oljer og er kjennetegnet ved deres IR strekkbånd ved 2160 cm-<1>. 5-ethyl-3-isocyanomethyl-1,2,4-oxadiazole, 5-methyl-3-isocyano-methyl-1,2,4-oxadiazole and 5-methoxymethyl-3-isocyanomethyl-1,2,4-oxadiazole are prepared in a similar manner. All compounds are oils and are characterized by their IR stretching band at 2160 cm-<1>.
c. 3-( 5-etyl-l ,2,4-oksadiazol-3-yl )-5 , 6-dihydro-5-metyl-6-okso-4H-7-trifluormetyl-imidazo(1,5-a)(1,4)benzodiazepin c. 3-(5-ethyl-1,2,4-oxadiazol-3-yl)-5,6-dihydro-5-methyl-6-oxo-4H-7-trifluoromethyl-imidazo(1,5-a) (1,4)benzodiazepine
3,4-dihydro-4-metyl-6-trifluormetyl-2H-1,4-benzodiazepin-2,5-(lH)dion (2 mmol) oppløses i 15 ml tørr dimetylformamid (DMF) og tilsettes 2,5 mmol K-t-butylat. Oppløsningen avkjøles under N2til 20°C, hvoretter 2,6 mmol klordietylfosfat tilsettes. 3,4-dihydro-4-methyl-6-trifluoromethyl-2H-1,4-benzodiazepine-2,5-(1H)dione (2 mmol) is dissolved in 15 ml of dry dimethylformamide (DMF) and 2.5 mmol of K-t is added -butylate. The solution is cooled under N 2 to 20°C, after which 2.6 mmol of chlorodiethyl phosphate are added.
Reaksjonsblandingen holdes under N2ved omrøring ved -20°C og tilsettes en -30°C kald oppløsning av 5-etyl-3-isocyanometyl-1,2,4-oksadiazol (2,7 mmol), som er fremstilt som beskrevet ovenfor, og K-t-butylat 2,6 mmol i 15 ml tørr DMF. The reaction mixture is kept under N2 with stirring at -20°C and a -30°C cold solution of 5-ethyl-3-isocyanomethyl-1,2,4-oxadiazole (2.7 mmol), which is prepared as described above, is added, and K-t-butylate 2.6 mmol in 15 ml dry DMF.
Den derved oppnådde blandingen får oppvarmes til romtemperatur, hvoretter den inndampes til tørrhet i vakuum. Den oljektige inndampingsresten behandles med HgO/eter. Den organiske fasen inndampes til tørrhet i vakuum, og inndampingsresten utkrystalliseres fra dietyleter for dannelse av 50 mg av den ovennevnte forbindelsen. The resulting mixture is allowed to warm to room temperature, after which it is evaporated to dryness in a vacuum. The oily evaporation residue is treated with HgO/ether. The organic phase is evaporated to dryness in vacuo, and the evaporation residue is crystallized from diethyl ether to give 50 mg of the above compound.
Smeltepunkt 230,4-231,3°C. Melting point 230.4-231.3°C.
3-(3-etyl-l,2,4-oksadiazol-5-yl)-7-metyl-5,6-dihydro-5-metyl-6-okso-4H-imidazo(1,5-a)(l,4)benzodiazepin, smeltepunkt 164°C, fremstilles på samme måte av 6-metyl-3,4-dihydro-4-metyl-2H-l,4-benzodiazepin-2,5(lH)-dion ved omsetning med 3-etyl-5-isocyanometyl-l,2,4-oksadiazol fremstilt som beskrevet ovenfor. 3-(3-ethyl-1,2,4-oxadiazol-5-yl)-7-methyl-5,6-dihydro-5-methyl-6-oxo-4H-imidazo(1,5-a)(l ,4)benzodiazepine, melting point 164°C, is prepared in the same way from 6-methyl-3,4-dihydro-4-methyl-2H-1,4-benzodiazepine-2,5(1H)-dione by reaction with 3- ethyl-5-isocyanomethyl-1,2,4-oxadiazole prepared as described above.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO890989A NO890989D0 (en) | 1985-03-08 | 1989-03-08 | ISOCYANOMETHYL COMPOUND AND PROCEDURE FOR THE PREPARATION OF AN OXADIAZOLIMIDAZOBENZODIAZEPINE DERIVATIVE. |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK108085A DK108085A (en) | 1985-03-08 | 1985-03-08 | NEW OXADIAZOLYLIMIDAZOBENZODIAZEPINE DERIVATIVES AND PROCEDURES FOR PREPARING IT |
DK108185A DK108185A (en) | 1985-03-08 | 1985-03-08 | NEW OXADIAZOLYLIMIDAZOBENZODIAZEPINE DERIVATIVES AND PROCEDURES FOR PREPARING IT |
DK220385A DK220385D0 (en) | 1985-05-17 | 1985-05-17 | PROCEDURE FOR THE PREPARATION OF OXADIAZOLYL DERIVATIVES OF IMIDAZOBENZODIAZEPINES AND INTERMEDIATES FOR USING THE PROCEDURE |
DK220485A DK220485D0 (en) | 1985-05-17 | 1985-05-17 | NEW OXADIAZOLYLIMIDAZOBENZODIAZEPINE DERIVATIVES AND PROCEDURES PREPARED THEREOF |
DK476985A DK476985D0 (en) | 1985-10-17 | 1985-10-17 | PROCEDURE FOR THE PREPARATION OF OXADIAZOLYL DERIVATIVES OF IMIDAZOBENZODIAZEPINES AND INTERMEDIATES FOR USING THE PROCEDURE |
NO860857A NO165545C (en) | 1985-03-08 | 1986-03-07 | ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE NEW OKSADIAZOLIMIDAZO-BENZODIAZEPINE DERIVATIVES. |
NO890989A NO890989D0 (en) | 1985-03-08 | 1989-03-08 | ISOCYANOMETHYL COMPOUND AND PROCEDURE FOR THE PREPARATION OF AN OXADIAZOLIMIDAZOBENZODIAZEPINE DERIVATIVE. |
Publications (2)
Publication Number | Publication Date |
---|---|
NO890989L true NO890989L (en) | 1986-09-09 |
NO890989D0 NO890989D0 (en) | 1989-03-08 |
Family
ID=27561798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO890989A NO890989D0 (en) | 1985-03-08 | 1989-03-08 | ISOCYANOMETHYL COMPOUND AND PROCEDURE FOR THE PREPARATION OF AN OXADIAZOLIMIDAZOBENZODIAZEPINE DERIVATIVE. |
Country Status (1)
Country | Link |
---|---|
NO (1) | NO890989D0 (en) |
-
1989
- 1989-03-08 NO NO890989A patent/NO890989D0/en unknown
Also Published As
Publication number | Publication date |
---|---|
NO890989D0 (en) | 1989-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0225013B1 (en) | Heterocyclic compounds and their preparation and use | |
KR101901044B1 (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
DE602004010151T2 (en) | COMPOSITIONS SUITED AS INHIBITORS OF PROTEIN KINASES | |
RU2100357C1 (en) | Heteroarylamines or their pharmaceutically acceptable salts and pharmaceutical composition based on thereof | |
DE60315062T2 (en) | TRIAZONE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOE | |
EP0150040A2 (en) | Imidazodiazepine derivatives | |
EP0241682B1 (en) | Novel benzodiazepine derivatives and their preparation and use | |
DK159150B (en) | Isocyanomethyl compound and process for preparing an oxadiazoleimidazobenzodiazepine derivative | |
EP0417631A2 (en) | Condensed diazepinones, process for their preparation, and medicaments containing these compounds | |
DE3850861T2 (en) | Imidazoquinoxaline compounds and their preparation and use. | |
JP5995841B2 (en) | 3,4-Dihydropyrrolo [1,2-a] pyrazine-2,8 (1H) -dicarboxamide derivatives, their preparation and therapeutic use thereof | |
AU627181B2 (en) | Imidazoquinoxaline compounds and their preparation and use | |
FI82049C (en) | Process for the preparation of 3- (5-cyclopropyl-1,2,4-oxadiazol-3-yl) -5,6-dihydro-5-methyl-6-oxo-4H-imidazo- (1.5) -a) (1,4) benzodiazepine | |
NO890989L (en) | ISOCYANOMETHYL COMPOUND AND PROCEDURE FOR THE PREPARATION OF AN OXADIAZOLIMIDAZOBENZODIAZEPINE DERIVATIVE. | |
US5053508A (en) | Fused heterotricyclic imides with psychotropic activity and intermedrates thereof | |
DE60107852T2 (en) | THIENOPYRROLIDINONE | |
DE3887064T2 (en) | Heterocyclic compounds and their production and use. | |
US5260298A (en) | Imidazatriazoloquinazoline compounds and their use | |
NO177749B (en) | Analogous Process for Preparation of 2,4,8-Tri-Substituted 3H, 6H-1,4,5a, 8a-Tetraazaacetaphthylene-3,5- (4H) -Diones | |
PT86154B (en) | A process for the preparation of novel pyrogolobenzimidazole and pharmaceutical compositions containing the same | |
DK154837B (en) | Oxadiazolylimidazobenzodiazepine compound and pharmaceutical preparation comprising it | |
AU7395098A (en) | 5-((Heteroaryl)Alkyl)-3-Oxo-Pyrido(1,2-a) Benzimidazole-4- carboxamide derivatives useful in treating central nervous system disorders | |
DK154142B (en) | Imidazo(1,5-a)quinoxaline compound, and preparation comprising it | |
DK155006B (en) | Fused imidazole derivatives, and pharmaceutical preparation comprising such a compound | |
JPH0329795B2 (en) |